Oncology Venture advancing towards next milestone in its clinical development of IXEMPRA®.

NEXT STORY
The Europe Vaccines Market is expected to reach US$ 16,291.0 Mn in 2027 from US$ 9,576.2 Mn in 2018
PREV STORY
Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA grants Breakthrough Device Designation for Roche’s Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma

author_avatar
NASDAQ Market News

Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

author_avatar
NASDAQ Market News

MULTIMEDIA UPDATE – Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

author_avatar
NASDAQ Market News